As the financial sector reels from government investigations in to incentive programs, a growing number of life sciences board members are asking whether they, too, could be missing critical risks related to their organizations’’ incentive programs. The answer may be yes.
Read more to find out the tough questions life sciences boards should be asking about their incentive programs.
Related content
Register to receive timely insights
Register to receive timely insights
Our practice
Our capabilities
Meet our team